Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)



Status:Completed
Conditions:High Cholesterol, Metabolic
Therapuetic Areas:Cardiology / Vascular Diseases, Pharmacology / Toxicology
Healthy:No
Age Range:18 - 64
Updated:11/30/2013
Start Date:January 2011
End Date:June 2012
Contact:Emily Jenkerson, B.A.
Email:jenkersone@WUSTL.EDU
Phone:314-362-1000

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

The purpose of this study is to determine the effect of maraviroc therapy in obese insulin
resistant subjects on:

1. Plasma triglyceride concentration

2. Plasma HDL-cholesterol and LDL-cholesterol concentrations

3. Plasma markers of cardiometabolic risk and inflammation


The purpose of this study is to determine, in obese insulin resistant subjects, the effect
of maraviroc therapy, a selective antagonist of the human chemokine receptor CCR5, on:

1. Plasma triglyceride concentration

2. Plasma HDL-cholesterol and LDL-cholesterol concentrations

3. Plasma markers of cardiometabolic risk and inflammation

Inclusion Criteria:

- obese (body mass index (BMI) between 30 and 45.9)

- increased plasma triglyceride concentrations (150-400 mg/dL)

Exclusion Criteria:

- active or previous infection with hepatitis B or C

- history of alcohol abuse

- current alcohol consumption (>20g/day)

- severe hypertriglyceridemia (>400 mg/dL)

- active peptic ulcer disease

- diabetes

- pregnant or lactating

- take statins, fibrates, niacin, moderate to strong Cyp3A4 inhibitors or inducers, or
any other medication that might confound interpretation of the study results will be
excluded.
We found this trial at
1
site
Washington University School of Medicine
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials